Randomized trial comparing 7 day and 5 day schedule of azacitidine for high-risk MDS -JALSG MDS212
Phase 3
- Conditions
- Myelodysplastic syndromes (RAEB and RAEB-t in FAB classification)
- Registration Number
- JPRN-UMIN000009633
- Lead Sponsor
- Japan Adult Leukemia Study Group (JALSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 410
Inclusion Criteria
Not provided
Exclusion Criteria
(1) AML with recurrent cytogenetic abnormality in WHO classification (2) With active malignancy (3) DM with poor control (4) With active infection (5) Under control with major tranquilizer (6) Pregnant women (7) Infection with HBV, HCV, or HIV (8) Those evaluated ineligible by attending doctors
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method